medical units enterprise backed by former Saracens rugby membership chairman Nigel Wray is ready to lift £15 million after revealing plans for a inventory market itemizing.
Belluscura will use the funds for the roll out of its light-weight and transportable oxygen concentrators that may change cumbersome steel cylinders in treating lung ailments.
Its X-PLO2R gadget, which acquired approval from US regulators in March, is ready to ship as much as 95% pure oxygen to sufferers 24 hours a day to assist enhance high quality of life.
The London and Texas-based firm can even look to progress different patents regarding oxygen enrichment units and coverings.
Belluscura is anticipated to be valued at between £50 million and £55 million on AIM following the inserting of shares with establishments later this month. Wray holds a 17% stake.
SPARK Advisory Companions is performing as adviser, whereas Dowgate Capital is sole dealer and bookrunner on the inserting.